Skip to main content

Table 2 Table 1

From: The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Model

Effect of imatinib

Reference

In vitro studies

  

Rat aortic endothelial cells

Protects endothelial barrier

[20]

Human umbilical vein endothelial cells

Protects endothelial barrier Improves cell-matrix adhesion

[3]

Human lung microvascular endothelial cells

Protects endothelial barrier

[3]

Immortalized endothelial cells

Protects endothelial barrier

[9]

Human umbilical vein endothelial cells

Protects endothelial barrier

[18]

Mouse lung microvascular endothelial cells

Protects endothelial barrier

[40]

In vivo studies

  

Bleomycin-induced lung injury

Anti-inflammatory

Anti-fibrotic

[35]

Isolated perfused lung model (mouse)

Inhibits lung vascular leak

[3]

Miles assay (mouse)

Attenuates vascular leak in skin

[3]

Cecal Ligation & Puncture (Sepsis) (mouse)

Attenuates vascular leak in lungs, kidneys

[3]

Intratracheal LPS (mouse)

Attenuates pulmonary edema

[18]

Ischemia-reperfusion in reperfusion lung

Reduces endothelial cytotoxicity

[40]

Miles assay (mouse)

Attenuates vascular leak in skin

[9]

Intratracheal LPS (mouse)

Attenuates vascular leak and inflammation

[23]

Cardiac bypass surgery

Attenuates vascular leak, improves perfusion, improves oxygenation

[19]

Clinical case reports (human)

  

Pulmonary veno-occlusive disease

Resolution of pulmonary edema

Improvement of oxygenation

[30]

Bleomycin-induced pneumonitis / lung injury

Resolution of pulmonary edema

[8]

Idiopathic pulmonary vascular leak

Resolution of generalized edema

Reduction of pulmonary vascular leak

Aman 2013

Drug-induced pneumonitis

Resolution of pneumonitis, case series

[22]